ERA4TB accelerates the development of new treatment regimens for tuberculosis.

Effects of the COVID-19 on the fight against tuberculosis

The general public is well aware of the tragic impact of the COVID-19 on the community in terms of lives, disruption of livelihoods and social distress. Far less obvious are the indirect effects that the outbreak exert on other major diseases of global incidence like tuberculosis. To contain the spread of the COVID-19, most countries have imposed strict lockdown measures that, however necessary, are negatively affecting the programs to eradicate tuberculosis at global level by hindering TB diagnosis, notifications and likely shortening the provision of drugs against the infection.

The Stop-TB Partnership has been working on a series of models to estimate the effect of the COVID-19 outbreak on the progress of TB at global scale. These models focus on three countries with a high burden of TB and distinct social settings that constitute paradigmatic cases within the spectrum of countries in which TB has a high incidence. In the worst-case scenario, the modelers estimated that a 3-month lockdown followed by a 10-month period to return to normality could lead to an additional 6.3 million cases of TB between 2020 and 2025, and an additional 1.4 million TB deaths during this time at global level. With these figures, the gains made in the fight against TB in the last five to eight years could be lost out. The study stresses that recovering the progress made in the last years will only be possible through increasing the efforts and investments in TB.

ERA4TB stands in solidarity with the additional difficulties that the present situation imposes on patients and professionals involved in treating TB. ERA4TB is committed with the development of new drugs of easy administration and effectivity against resistant strains, the consortium hopes to help mitigate the consequences of the COVID-19 outbreak on the battle against TB.

ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerate the development of new treatment regimens for tuberculosis.

Objectives

The main objective of ERA4TB is to create a European open platform to accelerate the development of new regimens for the treatment of tuberculosis.

Ambition

All Member States of WHO and the UN have committed to the goal of ending the TB epidemic by 2030 through their unanimous endorsement of WHO’s End TB Strategy at the World Health Assembly and their adoption of the UN Sustainable Development Goals (SDGs).

Ambition

All Member States of WHO and the UN have committed to the goal of ending the TB epidemic by 2030 through their unanimous endorsement of WHO’s End TB Strategy at the World Health Assembly and their adoption of the UN Sustainable Development Goals (SDGs).

Structure

The ERA4TB platform is based on a progression pipeline that can cater for a variety of molecules at different stages of development.

News

Follow our articles and ERA4TB news

Event

ERA4TB 5th Consortium Meeting: First F2F meeting in Madrid after the pandemic

On June 20th and 21st the fifth Consortium Meeting took place in Madrid. The meeting…
Event

5th Consortium Meeting on 20th and 21st of June 2022 – After 2 years, ERA4TB meets again face to face in Madrid

More than 120 representatives of ERA4TB partners are meeting face to face with the occasion…
News

ERA4TB welcomes CIM – Sant Pau (IIB Sant Pau) as New Partner

ERA4TB announced on the 4th Consortium Meeting that CIM – Sant Pau (IIB Sant Pau)…

Twitter

Follow us and be the first
to know what we do

In this interview with @NewsMedical, Head of Therapeutics Development Charles Wells discusses our current research into #tuberculosis, @WHO's new guidelines for TB care, and what inspired his career. Read more: https://bit.ly/3BJmYVt

👩‍💻📊Towards a more sustainable use of #AMR data: @IHIEurope project @FAIRplus_eu investigated in a case study the 'FAIRification' of @AMR_Combine data #StrongerTogether in the fight against #AMR and resistant #TB: https://twitter.com/FAIRplus_eu/status/1555154114924929025?s=20&t=trfEnNpti6-oxLFNz6xa6g

#antimicrobialstewardship #DataScience

FAIRplus@FAIRplus_eu

Many antimicrobial resistance data 🧫 are hardly reusable due to lack of #interoperability. ✨ Our #FAIRplus squad developed a new application ontology that combined several existing ontologies.

🙌 Read our case study on #IMI_COMBINE to find out more: https://fairplus-project.eu/news/fairplus-combine-case-study

Though tremendous progress against TB has been made in the last two decades, the world needs new interventions to prevent and treat this disease. At the Gates MRI, we're supporting and developing multiple vaccines and therapeutics urgently needed to improve outcomes and #endTB. https://twitter.com/TBAlliance/status/1546529505317212163

TB Alliance@TBAlliance

In the past 200 years, #tuberculosis has claimed over a billion lives. Now, TB kills more than 4,100 people every day. Learn more about how we can work together to fight one of the world's oldest diseases and finally #endTB: https://www.tballiance.org/

Please RT: Postdoctoral position available in mycobacteriology and single-cell technologies in the Microbial Individuality and Infection Lab at the Institut Pasteur in Paris. Please see details below.

"The biopharmaceutical industry agrees that we must use antibiotics judiciously, but those efforts are useless without a pipeline of novel antimicrobial treatments." #AMR https://www.washingtonpost.com/opinions/2022/07/29/superbugs-require-super-solutions/

Load More...

Know how accelerate the development of new treatment regimens for tuberculosis, discover our project

The Project